Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 10, 2010, Pages 652-661

  Graefe Mody, E U ^a   Jungnik, A ^a   Ring, A ^a   Woerle, H J ^a   Dugi, K A ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BI 1356; Interaction; Linagliptin; Pharmacokinetic; Pioglitazone

Indexed keywords

8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; CYTOCHROME P450 2C8; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PIOGLITAZONE;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; SINGLE BLIND PROCEDURE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

EID: 77957665412     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48652     Document Type: Article

References (32)

1. Takeda UK Ltd. Actos (pioglitazone) 15, 30 or 45 mg Tablets. Summary of Product Characteristics. Last date of revision: 21 April 2010.Available at: http://www.medicines.org.uk/EMC/medicine/4236/SPC/Actos%20Tablets/ (accessed May 2010).
2. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007; 21: 517-533.
3. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Disp. 2010; 38: 667-678.
4. Bohannon N. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med. 2009; 121: 40-45.
5. Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of Type 2 diabetes mellitus. Ann Pharmacother. 2007; 4: 51-60. (Pubitemid 46145957)
6. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of Type 2 diabetes. Expert Opin Investig Drugs. 2010; 19: 133-140.
7. Eckhardt M, Langkopf E, Mark M et al. 8-(3-(R)-aminopiperidin-1-yl)-7- but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of Type 2 diabetes. J Med Chem. 2007; 50: 6450-6453. (Pubitemid 350309082)
8. Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes. 2000; 108: 234-242.
9. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with Type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obesity Metab. 2007; 9: 166-174. (Pubitemid 46206560)
10. Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with Type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 1047-1056.
11. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in Type 2 diabetic patients. AmJ Physiol Endocrinol Metab. 2007; 292: 871-883.
12. Graal MB, Wolffenbuttel BH. The use of sulphonylureas in the elderly. Drugs Aging 1999; 15: 471-481.
13. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steadystate pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009; 25: 1963-1972.
14. Graefe-Mody U, Huettner S, Stähle H, Ring A, Dugi KA. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther. 2010; In press.
15. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male Type 2 diabetes patients. Diabetes Obes Metab. 2009; 11: 786-794.
16. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008; 48: 1171-1178.
17. Inzucchi SE. Oral antihyperglycemic therapy for Type 2 diabetes: Scientific review. JAMA. 2002; 287: 360-372. (Pubitemid 34256388)
18. Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol. 2006; 61: 70-78.
19. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: Potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006; 99: 44-51. (Pubitemid 44034394)
20. Karim A, Laurent A, Munsaka M,Wann E, Fleck P, Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009; 49: 1210-1219.
21. Kasliwal R, Wilton LV, Shakir SA. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf. 2008; 31: 839-850.
22. Langley AK, Suffoletta TJ, Jennings HR. Dipeptidyl peptidase IV inhibitors and the incretin system in Type 2 diabetes mellitus. Pharmacotherapy. 2007; 27: 1163-1180. (Pubitemid 47173660)
23. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
24. Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with Type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther. 2003; 25 (Suppl): 64-80.
25. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009; 25: 2361-2371.
26. Rosenstock J, Brazg R, Andryuk PJ et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with Type 2 diabetes:A24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28: 1556-1568. (Pubitemid 44841980)
27. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with Type 2 diabetes. Diabetes Obesity Metab. 2007; 9: 175-185. (Pubitemid 46206561)
28. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008; 325: 175-182. (Pubitemid 351439162)
29. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3- methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther. 2009; 328: 556-563.
30. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf. 2009; 32: 409-418.
31. Yamashita K, Murakami H, Okuda T, Motohashi M. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine. J Chromatogr B Biomed Appl. 1996; 677: 141-146.
32. FDA Draft Guidance on Drug Interactions. US FDA Center for Biologics Evaluation and Research (CBER), September 2006. Available at: http://www.fda.gov/Drugs/DevelopmentApproval Process/DevelopmentResources/ DrugInteractions Labeling/ucm093606.htm (accessed January 14, 2010).